Cefepime vs. Carbapenems for Treating AmpC β-lactamase-producing Enterobacteriaceae Bloodstream Infections

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05535751

Acronym

CARBAPENEM

Enrollment

200

Registered

2022-09-10

Start date

2022-07-20

Completion date

2023-06-20

Last updated

2023-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacteremia

Keywords

Bacteremia, Cefepime, carbapenems, AmpC β-lactamase, enterobacteriaceae bloodstream infections

Brief summary

Recent international recommendations suggest the use of carbapenem rather than cefepime in this situation, but with a low level of evidence, given the few existing studies. As cefepime is a less broad-spectrum antibiotic than carbapenems, its use would limit the selection of multidrug-resistant bacteria.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patient (≥18 years of age) * managed within a study center for high-grade cephalosporinase-producing bacteremia * Not objecting to the reuse of their health data for scientific research purposes.

Exclusion criteria

* Patient who has expressed opposition to the reuse of their data for scientific research purposes. * Resistance to Cefepime or carbapenems * Multiple bacteremia * Treatment with a molecule other than Cefepime or carbapenem.

Design outcomes

Primary

Measure	Time frame
Hospital mortality	30 days after infection

Countries

France

Outcome results